• MeSH
• Cytochrome P-450 CYP3A metabolism   MeSH
• H(+)-K(+)-Exchanging ATPase administration & dosage   pharmacokinetics   metabolism   MeSH
• Helicobacter Infections drug therapy   MeSH
• Proton Pump Inhibitors administration & dosage   pharmacokinetics   pharmacology   MeSH
• Drug Interactions MeSH
• Humans MeSH
• Omeprazole pharmacokinetics   metabolism   adverse effects   MeSH
• Peptic Ulcer drug therapy   MeSH
• Ticlopidine metabolism   MeSH
• Warfarin metabolism   MeSH
• Check Tag
• Humans MeSH

Zavedení inhibitorů protonové pumpy (IPP) do klinické praxe významně ovlivnilo léčbu gastroezofageálního refluxu, infekce H. pylori a peptického vředu. V současné době je na trhu k dispozici pět inhibitorů protonové pumpy: omeprazol a jeho izomerická forma esomeprazol, pantoprazol, lansoprazol a rabeprazol (v ČR pouze omeprazol, pantoprazol a lansoprazol). Rozdíly mezi jednotlivými IPP spočívají v mechanismu účinku, farmakokinetice, nežádoucích účincích a v interakcích s ostatními farmaky. Z hlediska klinické praxe jsou však rozdíly mezi IPP používanými u nás minimální.

The introduction of proton pump inhibitors (PPIs) into clinical practice has had a significant impact on the treatment of gastroesophageal reflux, H. pylori infection and peptic ulcer disease. Five PPIs are currently marketed: omeprazole and its isomer esomeprazole, pantoprazole, lansoprazole and rabeprazole, but in the Czech Republic, only omeprazole, pantoprazole and lansoprazole are available. PPIs differ from each other in the mechanism of action, pharmacokinetics, adverse effects and drug-drug interactions. From the perspective of clinical practice, the differences between currently available PPIs in the Czech Republic are minimal.

• MeSH
• Cytochrome P-450 CYP3A metabolism   MeSH
• H(+)-K(+)-Exchanging ATPase administration & dosage   pharmacokinetics   metabolism   MeSH
• Helicobacter Infections drug therapy   MeSH
• Proton Pump Inhibitors administration & dosage   pharmacokinetics   pharmacology   MeSH
• Drug Interactions MeSH
• Humans MeSH
• Omeprazole pharmacokinetics   metabolism   adverse effects   MeSH
• Peptic Ulcer drug therapy   MeSH
• Ticlopidine metabolism   MeSH
• Warfarin metabolism   MeSH
• Check Tag
• Humans MeSH

• MeSH
• 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage   pharmacology   MeSH
• H(+)-K(+)-Exchanging ATPase metabolism   therapeutic use   MeSH
• Proton Pump Inhibitors administration & dosage   pharmacology   adverse effects   MeSH
• Humans MeSH
• Peptic Ulcer drug therapy   MeSH
• Check Tag
• Humans MeSH

• MeSH
• Cysteine pharmacology   MeSH
• Research Support as Topic MeSH
• H(+)-K(+)-Exchanging ATPase metabolism   MeSH
• Yeasts metabolism   MeSH
• Copper microbiology   MeSH
• In Vitro Techniques MeSH
• Iron metabolism   MeSH